Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | HINT1 | P49773 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18927167 | 0.98 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL21591932 | 0.98 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL21073923 | 0.98 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL17304163 | 0.98 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL18954874 | 0.98 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL19493308 | 0.98 | TYMP (0.43) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL19493331 | 0.95 | TYMP (0.41) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL23138150 | 0.94 | TYMP (0.45) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL668619 | 0.94 | TYMP (0.45) | TYMPKDM4ETAS1R3TAS1R1HPGD | |
| SCHEMBL30866953 | 0.93 | TYMP (0.44) | TYMPKDM4ETAS1R3TAS1R1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2899278-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals Inc. (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150011608-A1 | iRNA Agents Targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
| EP-2636739-B1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS INC (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2636739-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-2365077-B1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS INC (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130018085-A1 | iRNA Agents Targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2013-01-17 | — | — | US | disclosed |
| US-8293719-B2 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120045461-A1 | Compositions and Methods for Inducing an Immune Response in a Mammal and Methods of Avoiding an Immune Response to Oligonucleotide Agents Such as Short Interfering RNAs | ALNYLAM PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110224282-A1 | iRNA Agents Targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2365077-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7919473-B2 | IRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20060223770-A1 | IRNA agents targeting VEGF | ALNYLAM EUROPE AG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-20060217330-A1 | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs | BANK OF AMERICA, N.A. | 2006-09-28 | — | — | US | disclosed |
| US-20060094032-A1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6686463-B2 | FEWER SYNTHETIC STEPS; INVOLVES FORMATION OF A 5',4'-BRIDGING SILYL PROTECTING GROUP TO FORM A FUSED SILOXANE ON THE FURAN RING | SIRNA THERAPEUTICS, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1313752-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002018405-A2 | METHODS FOR SYNTHESIZING NUCLEOSIDES, NUCLEOSIDE DERIVATIVES AND NON-NUCLEOSIDE DERIVATIVES | RIBOZYME PHARMACEUTICALS, INCORPORATED (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094032-A1 | iRNA agents targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885KDM4E 3027/4885TAS1R3 3615/4885 |
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 16/4885KDM4E 1810/4885TAS1R3 3530/4885 |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 17/4885KDM4E 1814/4885TAS1R3 3980/4885 |
| US-20130018085-A1 | iRNA Agents Targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885KDM4E 3027/4885TAS1R3 3615/4885 |
| US-20060223770-A1 | IRNA agents targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885KDM4E 3027/4885TAS1R3 3615/4885 |
| US-20110224282-A1 | iRNA Agents Targeting VEGF | KDR, FLT4, SNRPE | TYMP 1464/4885KDM4E 3027/4885TAS1R3 3615/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | TYMP 14/4885KDM4E 1689/4885TAS1R3 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.